Aspira Women's Health Inc. · OTC:AWHL
Aspira Women's Health — Vermillion — Proxy Contest (February 2013)
40 slides from Aspira Women's Health's proxy contest presentation, Feb 21, 2013
Slide 1: Vermillion, Inc. Schedule 14A
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ ¨ Check the appropriate box: ¨ Pre
Slide 2: Filing Party and Date Filed
(3) Filing Party: (4) Date Filed:
Slide 3: ISS Presentation, February 21, 2013
ISS Presentation February 21, 2013
Slide 4: Forward-Looking Statements
Forward-Looking The “may,” intentions. introduced and actual Should This expected. 1All logos, are following presentation results, “are one subject trademarks Such by or expected performance the more information tostatements is company certain Statements copyright ofto,” and these risks, “will,” bra
Slide 5: Executive Summary
EXECUTIVE SUMMARY
Slide 6: Corporate Vision
Corporate 3To becomeVision a recognized leader in the advancement of women’s health by providing innovative methods to detect, monitor and manage the treatment of gynecologic cancers and other related diseases
Slide 7: Who We Are
Who As In OVA1 Our 42. Proteomics collaboration an flagship expanding we industry represents are…product, isleader patent with the a new large-scale prestigious in OVA1®, portfolio class Proteomics2, ofis helps study software-based research the first sustain of weproteins, discover institutions, FDA
Slide 8: Unique, Proven, Industry-Leading Strengths
Unique Proven Industry-Leading >10-yr “Gordian Innovation Renowned OVA1® Ability Result: Outsourced/Flexible Core Clinical, 5Enables collaborations alliance Strengths to IP, Translational rapid “firsts” QA, knot” leverage papers, Clinical includes RA, response with approach open Offer Discovery FDA
Slide 9: Renowned Partnerships and Expected Milestones
Renowned Potential Post-surgical Dr. Presurgical 6(1) Estimated. Fred Coleman John Rob Ueland Martignetti collaborator Clinical diagnosis monitoring, Expected (U(M.D. Partnerships Kentucky) (Mt. & fortriage milestones Anderson) OvaDx Sinai, prognosis of –NYC) Set OVA1® endometrial – aid –are the ICS
Slide 10: Diagnostic Patent Portfolio
#Diagnostic Disease Families Ovarian PAD Alzheimer’s Breast Other TOTAL 710ofnew Patent 43cancer 5patents 2Area 31 cancer 1U.S. - Patents Patent 15disease 4Non-U.S. 7granted 17 1 -Portfolio 4Issued 34 3or 2 /allowed Allowedsince January 2011 7 new biomarker patent families acquired from Correlogic
Slide 11: Ovarian Cancer Franchise / OVA1
OVARIAN CANCER FRANCHISE / OVA1®
Slide 12: Ovarian Cancer: Unmet Clinical Need
OVA1 Lifetime -Ovarian Only 5-year 3. Key Mass Adnexal % Cases IStage II III 9IV This More 22,000 Only 24% 6% Surveillance, of 55% 15% to 5-year 165% Rate relates 95% Addresses survival 19% Survival: than in15-30% 0-20% cancer determined risk 3 women are Survival 1of to million rates is diagnosed >1
Slide 13: Limitations of Traditional Approaches to Diagnosis
What’s CA125 Before Misleading: Transvaginal Unreliable: Variable: Physical Limited 100,000 50,000 35,000 ~1,000 Just 10 1,000 OVA1, General OB/GYNS GOs the Blood #Family exam Results of Gynecologic Problem 50% evaluation Elevated Gynecologic Ultrasound/Imaging Test CA125 not Surgeons Practitioners
Slide 14: The OVA1 Solution
The OVA1 while test”) a“As Society 4. 5. 11gynecologic Ueland http://www.sgo.org/newsroom/position-statements-2/ova1/ Solution: physicians and 95% isofan represents FR, Gynecologic negative FDA-cleared OVA1® oncologist DeSimone who predictive are a new Oncology, expert is CP, blood class indicated.”
Slide 15: How OVA1 Is Used
How -“Using Society Lower Treated Higher Specialist 12 Dr. Beth OVA1 Probability Probability OVA1 of byInvolved Y. Gynecologic OB/GYN isKarlan, to Typically better of of2005 Malignancy Malignancy triage Oncology Used: President, women The OVA1® with a Diagnostic pelvic massPathway may lead to improv
Slide 16: Validated Study Results
Validated >1,000 Study Total: 4. 6. 7. 13 Ueland Miller R.E.44 2Bristow 1adnexal sites: sites &R, Through FR, 2 Smith sites: :17 DeSimone 17surgeries et al. 10 A, 44/DeSimone Clinical Gynecologic >250 CP, Seamon Sites4,6,7 various C, et Oncology al. LG, malignancies Obstet et al.128 Gynecol. Obstet
Slide 17: OVA500 Multi-Center Study
OVA1®: OVA500 Outstanding >1,000 Overall Confirms Gynecologic Principal “Thanks determinants Dr. 7. 14 R.E. Robert Bristow patients both to KEY OVA500 Investigator the E. diagnostic performance studies Oncology of unrivaled Bristow TAKEAWAYS in et survival.” al. combined Multi-Center identified /for
Slide 18: OVA500 Combined Performance Results
OVA1®: New OVA500 Combined Sensitivity Physician Overall Premenopausal Population 94% Early 91% Cancer 7. 15 R.E. 91% OVA500 Stage Bristow (Stage 96% Multi-Center OVA500 Assessment w/ NPV Premenopausal Ovarian 98% Risk Imulti-site Early et & Overall al. II) Multi-Center Stratification Premenopausal
Slide 19: OVA1 vs ROMA Performance
Stand ROMA OVA1 4. 8. 16 Ueland ROMA® Alone (n=) maintains (n=) FR, 39/40 (HE4 Performance Sensitivity 9/12 DeSimone a34/34 52/52 EIA high+level of 26/38 57/68 Architect CP, OVA14 of Seamon 71/86 149/161 sensitivity CA125 & ROMA8 LG, II™) et across al. Instructions Obstet a broad Gynecol. range Foro
Slide 20: Expanding OVA1 Payer Coverage
OVA1 27 47 Medicare (BCBS) 45 Department Advantage Other 1.5 with Total Highmark BCBS (Millions 36M 41M 47M47M Q2 5M 10M 21M 30M 2010 17 Blue million Q3 million Quest 36M 2011 Lives 94.9 payors Expanding Coverage Q4 Cross of /36M million of Q1 2012 Medicare Diagnostics Currently of Lives) Medicare c
Slide 21: New CPT Code Effective January 2013
Newuse AMA accelerates CMS will CPT® They 18 AMA provides (Centers assigned (Current “gap-fill” CPT expanding uniform for aProcedural Code unique Medicare process –coverage language aCategory Watershed toTerminology) &determine Medicaid and that 1 CPT adoption Industry accurately CPT Services) Code
Slide 22: OVA1 Growth and Clinical Success
OVA1 Nearly coverage Growth 2013 Performed 9. 20 Guidance Clinical 38K indecisions, OVA1 Since tests issued &FDA ordered Tests Commercial and i.e.,Clearance effective Medicare through Success only 2012 andon Blue Demonstrates >5,371 11-12-2012 Cross ordering BlueStrong Shield physicians Growth Posit
Slide 23: Expanding Indications and Product Roadmap
Expand extension Ovarian U.S. Indication Triage Adnexal High Drug Monitoring & TBD 10. 21 Prediction Approximate Target Risk Selection 300k OVA1 Cancer Market Masses for Testpresurgical use Population10 Roadmap Opportunity Xestimates, to 1 Million include monitoring based risk assessment on Vermilli
Slide 24: Vascular Medicine Program / Peripheral Artery Disease
VASCULAR MEDICINE PROGRAM / PERIPHERAL ARTERY DISEASE 23
Slide 25: PAD Prevalence and Market Opportunity
PAD Prevalence Obese Early Currently “In (1) At U.S. Diabetics (Millions) Smokers Elderly (Less TOTAL 24 Risk Steg the Market diagnosis Overlap) people next aged Group(3) 59.3 etaged aged no al, offive Opportunity 65+ blood JAMA, aged PAD 50+ 50+ (11.5) and years, 38.0 Population 19.6 50+ test is 13
Slide 26: PAD Initial Study Results
Positive PAD 1,025 Identified Results Publication Study Society “…Results 25 intended subjects results recently for Initial PAD indicate Vascular would were use were Study inpresented 17 study: further presented this studied Medicine of Results 20 biomarker build at (85%) byan at for 2012 researcher
Slide 27: Seeking a Development Partner for PAD
Seeking A Additional 26significant Development product marketdevelopment opportunity Partner forand exists Peripheral clinical Extensive Artery trial work intended Disease is required use (PAD) study This completed is the best Requires avenue cardiology to realize value market forsegment our PADexpe
Slide 28: Management Team
MANAGEMENT TEAM 27
Slide 29: Management Team Experience
Management Deep Title Hybritech, Bruce Molecular Beckman Senior Donald Business Munroe, Capitol Biopharmaceuticals William Abbott Chief Eric Officer 28 Schoen Experience management Accounting Scientific A. Vice Diagnostics Alticast, Vial, G. B. Ph.D. Huebner Development Coulter, Diagnostics (Microar
Slide 30: Board of Directors
BOARD OF DIRECTORS 29
Slide 31: Board of Directors Experience
BoardTherapeutics, Established development Title James Hybritech, Bruce Philadelphia Diagnostics John Financial Pain Peter Laboratories, Carl William Severinghaus Wallen, Director 30 Experience F. S. A. of S.Hamilton Ph.D. Roddy C. Tecan Burns Directors Huebner Officers Gen-Probe, IDEXX Board Nation
Slide 32: Board Committees
Board J. Chairman Audit Governance Compensation Business Interim *Committee 31 Burns Committee Committees CEO W. Dev 9 Wallen, Cmte Chairman 9Cmte Cmte 99 9*99 PhD. 99* 99* 9 C. Severinghaus P. Roddy B. Huebner
Slide 33: Board Qualifications Matrix
Board Age Industry J. B. W. P. C. Robin Robert 32 Burns Roddy Huebner Severinghaus Wallen, Healthcare Vedova Qualifications Goggin 66 &53Sales PhD. 962 99 959 99 48 9Board 60 69 Mgmt 999 99999 9/9Experience 9Finance 9999 9 Marketing Int’l R&D General Comp
Slide 34: New Board Nominee Robert Goggin
NewBoard Robert Mr. No 33 medical experience Goggin’s Board S. Goggin Audit Governance Compensation experience Nominee reimbursement lack inCommittee with managing ofFDA Qualifications: ofexperience any committee submissions experience or experience kind operating experience or acompliance Healthcar
Slide 35: History of Mr. Goggin's Board Seat Request
History The In court We of Mr. This 34 2011, June $500,000. offered Goggin’s Goggin Court Proxy filings. 2012, of Mr. of interaction contest aand toGoggin Unacceptable Case Board the History The accept his Chancery Group was isGroup Seat filed Mr. awith dismissed wasteful to Novak Bessenyei filed su
Slide 36: New Board Nominee: Elect Robin Dellaveдова
New Board Elect Robin related Pertinent 35 Roberta has to international our the Nominee industry L. following (Robin) Knowledge market industry Dellaexperience Vedova credentials of “how to Adding fill to” tothe manage beopen aawoman productive Board a start toofthe upcontributing Directors laborato
Slide 37: Approve Stock Incentive Plan Share Increase
Stockfor Approve Used versus cash 36 to Incentive cash attract athe company Without increase the Plan best of additional ofour possible 1,300,000 size shares newauthorized management it will beshares difficult and employees to impossible – in to particular competeour forCEO talentposition over compe
Slide 38: Approve Compensation
Approve Compensation Vermillion annual 37 compensation Annual routinely Compensation retains for 2013 outside at $252,000 professional plus acompensation $50,000 bonusexperts package to evaluate and 100,000 employee stock options compensation is well versus below industry standards Vermillion Our ma
Slide 39: Key Takeaways
Key Vermillion Experienced -Success Broad 38 Nearly 5,371 Strengthening NewTakeaways patent CPT OVA500 ordering with 38K iscode, Board portfolio first an tests trends study emerging physicians effective commercial ordered andconfirms supports inManagement OVA1 industry through January to date produc
Slide 40: Contact Information
Contact TX Corporate Vermillion, Austin, 39 Information Headquarters 78738 Inc. Interim [email protected] CEO Bruce12117 A. Huebner Bee CavesTel: Rd.(512) Vermillion, 519.0400 Inc.Fax: Building (512) 439.6980 3, Suite 100 www.vermillion.com 512-519-0422